Letrozole

from Wikipedia, the free encyclopedia
Structural formula
Structural formula of Letrozole
General
Non-proprietary name Letrozole
other names

4,4 '- (1 H -1,2,4-triazol-1-ylmethylene) bisbenzonitril

Molecular formula C 17 H 11 N 5
External identifiers / databases
CAS number 112809-51-5
EC number 675-034-8
ECHA InfoCard 100.200.357
PubChem 3902
DrugBank DB01006
Wikidata Q194974
Drug information
ATC code

L02 BG04

properties
Molar mass 285.30 g mol −1
Physical state

firmly

Melting point

181-183 ° C

safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances
no GHS pictograms
H and P phrases H: no H-phrases
P: no P-phrases
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Letrozole is a drug from the group of aromatase inhibitors . It is taken orally. Letrozole was patented by Ciba-Geigy in 1989 under the brand name Femara and is used in the treatment of primary and metastatic breast cancer in postmenopausal women.

Mechanism of action

Letrozole inhibits excessive aromatization from androgens to estrogens. The effect and strength is similar to that of anastrozole .

Abuse as a doping agent

The active ingredient was placed on the prohibited list by the World Anti-Doping Agency (WADA) in 2008 . Possession of more than 75 mg is assessed as a "not small amount" according to the Medicines Act , according to the doping agent quantity regulation .

Side effects

  • Hot flashes and rednesses (flushes)
  • fatigue
  • a headache
  • nausea
  • depressions
  • sleep disorders
  • Muscle and joint pain

literature

Individual evidence

  1. ↑ a b Data sheet Letrozole, ≥98% (HPLC) from Sigma-Aldrich , accessed on November 29, 2012 ( PDF ).
  2. ↑ a b Entry on Letrozole. In: Römpp Online . Georg Thieme Verlag, accessed on July 13, 2019.